- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00071929
Oxaliplatin in Treating Patients With Persistent or Recurrent Endometrial Cancer
Phase II Evaluation of Oxaliplatin in the Treatment of Recurrent or Persistent Endometrial Carcinoma
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of oxaliplatin in treating patients who have persistent or recurrent endometrial cancer.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
OBJECTIVES:
- Determine the antitumor activity of oxaliplatin in terms of response rate in patients with persistent or recurrent endometrial carcinoma that is refractory to curative or established therapy.
- Determine the nature and degree of toxicity of this treatment regimen in these patients.
OUTLINE: This is a multicenter study.
Patients receive oxaliplatin IV over 2 hours on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for 2 years and then every 6 months for 3 years.
PROJECTED ACCRUAL: Approximately 19-51 patients will be accrued for this study.
Type d'étude
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
Alabama
-
Birmingham, Alabama, États-Unis, 35294-3300
- University of Alabama at Birmingham Comprehensive Cancer Center
-
-
Arizona
-
Phoenix, Arizona, États-Unis, 85006-2726
- CCOP - Western Regional, Arizona
-
-
California
-
Orange, California, États-Unis, 92868
- Chao Family Comprehensive Cancer Center at University of California Irvine Cancer Center
-
-
Colorado
-
Denver, Colorado, États-Unis, 80010
- University of Colorado Cancer Center at University of Colorado Health Sciences Center
-
-
Connecticut
-
New Britain, Connecticut, États-Unis, 06052
- New Britain General Hospital
-
-
Delaware
-
Newark, Delaware, États-Unis, 19713
- CCOP - Christiana Care Health Services
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60637-1470
- University of Chicago Cancer Research Center
-
Chicago, Illinois, États-Unis, 60612
- MBCCOP - University of Illinois at Chicago
-
Decatur, Illinois, États-Unis, 62794-9640
- CCOP - Central Illinois
-
Evanston, Illinois, États-Unis, 60201
- CCOP - Evanston
-
Urbana, Illinois, États-Unis, 61801
- CCOP - Carle Cancer Center
-
-
Indiana
-
South Bend, Indiana, États-Unis, 46617
- Saint Joseph Regional Medical Center
-
-
Kansas
-
Kansas City, Kansas, États-Unis, 66160-7357
- Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
-
-
Michigan
-
Ann Arbor, Michigan, États-Unis, 48106
- CCOP - Michigan Cancer Research Consortium
-
Grand Rapids, Michigan, États-Unis, 49503
- CCOP - Grand Rapids
-
Kalamazoo, Michigan, États-Unis, 49007-3731
- CCOP - Kalamazoo
-
-
Minnesota
-
Saint Louis Park, Minnesota, États-Unis, 55416
- CCOP - Metro-Minnesota
-
-
Mississippi
-
Jackson, Mississippi, États-Unis, 39216-4505
- University of Mississippi Medical Center
-
-
Missouri
-
Columbia, Missouri, États-Unis, 65203
- Ellis Fischel Cancer Center at University of Missouri - Columbia
-
Kansas City, Missouri, États-Unis, 64131
- CCOP - Kansas City
-
Springfield, Missouri, États-Unis, 65807
- CCOP - Cancer Research for the Ozarks
-
-
Nebraska
-
Omaha, Nebraska, États-Unis, 68106
- CCOP - Missouri Valley Cancer Consortium
-
-
New York
-
Brooklyn, New York, États-Unis, 11203
- SUNY downstate Medical Center
-
Stony Brook, New York, États-Unis, 11790-7775
- Long Island Cancer Center at Stony Brook University Hospital
-
-
North Carolina
-
Chapel Hill, North Carolina, États-Unis, 27599-7295
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
-
-
Ohio
-
Cleveland, Ohio, États-Unis, 44106
- Ireland Cancer Center
-
Cleveland, Ohio, États-Unis, 44124
- Cleveland Clinic Taussig Cancer Center
-
Columbus, Ohio, États-Unis, 43222
- Mount Carmel West Hospital
-
-
Oklahoma
-
Oklahoma City, Oklahoma, États-Unis, 73190
- University of Oklahoma College of Medicine
-
-
Oregon
-
Portland, Oregon, États-Unis, 97225
- CCOP - Columbia River Oncology Program
-
-
Pennsylvania
-
Abington, Pennsylvania, États-Unis, 19001-3788
- Abington Memorial Hospital
-
Danville, Pennsylvania, États-Unis, 17822-2001
- CCOP - Geisinger Clinic and Medical Center
-
Hershey, Pennsylvania, États-Unis, 17033-0850
- Penn State Cancer Institute at Milton S. Hershey Medical Center
-
Philadelphia, Pennsylvania, États-Unis, 19111
- Fox Chase Cancer Center
-
Pittsburgh, Pennsylvania, États-Unis, 15213-3180
- Magee-Womens Hospital
-
-
Tennessee
-
Knoxville, Tennessee, États-Unis, 37917
- Southeast Gynecologic Oncology Associates
-
Nashville, Tennessee, États-Unis, 37232-2516
- Vanderbilt-Ingram Cancer Center at Vanderbilt Medical Center
-
-
Texas
-
Temple, Texas, États-Unis, 76508
- CCOP - Scott and White Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
DISEASE CHARACTERISTICS:
Histologically confirmed endometrial carcinoma that is refractory to curative therapy or established treatment
- Clinically and/or histologically confirmed persistent or recurrent disease
Measurable disease by physical examination or medical imaging
- Sonography allowed if lesions are clearly defined on initial examination and bidimensionally measurable
- Ascites or pleural effusions not considered measurable
Must have received 1 prior cytotoxic therapy regimen
- May include high-dose therapy, consolidation, or extended therapy after surgical or nonsurgical assessment
1 additional noncytotoxic regimen allowed
Biologic or cytostatic agents include, but are not limited to:
- Monoclonal antibodies
- Cytokines
- Small-molecule inhibitors of signal transduction
- Ineligible for a higher priority GOG protocol
- No known brain metastases
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- GOG 0-2 if received 1 prior therapy regimen
- GOG 0-1 if received 2 prior therapy regimens
Life expectancy
- Not specified
Hematopoietic
- Absolute neutrophil count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
Hepatic
- Bilirubin no greater than 1.5 times upper limit of normal (ULN)
- SGOT no greater than 2.5 times ULN
- Alkaline phosphatase no greater than 2.5 times ULN
Renal
- Creatinine no greater than 1.5 times ULN
Cardiovascular
- No symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia
Neurologic
- No sensory or motor neuropathy greater than grade 1
- No residual neuropathy attributed to prior chemotherapy or other chronic conditions (e.g., diabetes, venous stasis, or carpal tunnel syndrome)
Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No history of allergy to platinum compounds or antiemetics
- No active infection requiring antibiotics
- No other uncontrolled illness
- No other invasive malignancies within the past 5 years except nonmelanomatous skin cancer
PRIOR CONCURRENT THERAPY:
Biologic therapy
- See Disease Characteristics
- At least 14 days since prior pegfilgrastim
- At least 24 hours since other prior growth factors
- At least 3 weeks since prior biologic or immunologic therapy
- No concurrent growth factors during first course of study therapy
Chemotherapy
- See Disease Characteristics
- At least 4 weeks since prior chemotherapy and recovered
- No more than 1 prior cytotoxic chemotherapy regimen, either single or combination cytotoxic drug therapy
- No prior oxaliplatin
Endocrine therapy
- At least 1 week since prior hormonal therapy directed at tumor
- Concurrent hormone replacement therapy allowed
Radiotherapy
- At least 4 weeks since prior radiotherapy and recovered
Surgery
- Recovered from any recent surgery
Other
- At least 3 weeks since prior therapy for endometrial cancer
- No other concurrent investigational agents
- No prior anticancer therapy that would preclude study participation
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Masquage: Aucun (étiquette ouverte)
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chaise d'étude: Paula M. Fracasso, MD, PhD, Washington University Siteman Cancer Center
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- CDR0000068235
- GOG-0129K
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Cancer de l'endomètre
-
IVI MadridIgenomixComplété
-
National Cancer Institute (NCI)ComplétéPoumon | Cerveau | Sein | Prostate | EndometrialÉtats-Unis
-
PfizerRetiréCancer du sein | Cancer des ovaires | Cancer du poumon non à petites cellules (NSCLC) | Tumeurs solides | Liposarcome | Endometrial
-
Western Regional Medical CenterRésiliéCancer du pancréas | Cancer du poumon non à petites cellules | Cancer avancé | Cancer des cellules rénales | Carcinome colorectal | Endometrial | UtérinÉtats-Unis
Essais cliniques sur oxaliplatine
-
SanofiComplété
-
SanofiComplétéCancer de l'estomacCorée, République de
-
SanofiComplétéTumeurs pancréatiquesCanada